Summaries for Patients |

The Cost-Effectiveness of Preventive Strategies for Breast and Ovarian Cancer for Women with BRCA1 or BRCA2 Mutations FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation.” It is in the 21 March 2006 issue of Annals of Internal Medicine (volume 144, pages 397-406). The authors are K. Anderson, J.S. Jacobson, D.F. Heitjan, J. Graff Zivin, D. Hershman, A.I. Neugut, and V.R. Grann.

Ann Intern Med. 2006;144(6):I-40. doi:10.7326/0003-4819-144-6-200603210-00002
Text Size: A A A

What is the problem and what is known about it so far?

Mutations on breast cancer suppressor genes (BRCA1 and BRCA2) have been shown to increase the risk for breast and ovarian cancer. Genetic testing identifies women who might consider cancer screening or treatments to prevent developing cancer. However, not all women with one of these mutations will develop cancer, so identification of mutations may also needlessly expose women to unnecessary interventions to prevent cancer. Interventions to prevent cancer include oral contraceptives to reduce ovarian cancer risk, the drug tamoxifen to reduce breast cancer risk, and surgical removal of the ovaries (bilateral salpingo-oophorectomy) or the breasts (bilateral mastectomy). The balance among the costs, harms, and benefits of these various options is unclear.

Why did the researchers do this particular study?

To evaluate the costs, harms, and benefits of strategies that are currently available to women who have BRCA1 or BRCA2 mutations.

Who was studied?

Instead of studying actual patients, the researchers used a computer model to simulate what would happen to a virtual group of women with BRCA1 or BRCA2 mutations if they chose different preventive strategies.

How was the study done?

The researchers collected information about the risk for cancer in women with the mutations and their likely outcomes. They also collected information about the benefits, harms, and costs of 6 different strategies: oral contraceptives, tamoxifen, bilateral salpingo-oophorectomy, bilateral mastectomy, both surgeries, or surveillance. Surveillance meant careful follow-up with yearly mammography and breast examinations with breast ultrasonography, if needed, and gynecologic examinations with pelvic ultrasonography and blood tests every 6 months. The researchers used this information to develop a computer model that simulated what would happen to women with BRCA1 or BRCA2 mutations who chose each of the 6 options. The computer model considered costs, harms, and benefits in weighing the various options. The model also considered the value of certain outcomes over others. For example, the model assumed that women valued survival with their breasts intact higher than survival after mastectomy.

What did the researchers find?

Oophorectomy alone or with mastectomy resulted in the best balance between costs and benefits for 35-year-old women at high risk for cancer because of a BRCA mutation. The model showed that mastectomy becomes more favorable as women become older.

What were the limitations of the study?

These results depend on the accuracy of the computer model and may differ from what would happen in real life. In addition, how a particular woman values certain outcomes over others may differ from the values that the researchers used in their model.

What are the implications of the study?

Oophorectomy and oophorectomy with mastectomy seem to be the most cost-effective strategies to prevent breast and ovarian cancer in women at high risk for cancer because of BRCA1 or BRCA2 mutations. However, many factors will go into women's decisions about whether to have genetic testing and what to do if they have positive test results. It is hoped that this paper will help make policymakers and insurance companies more willing to pay for these preventive treatments when women want to have them.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.